Production (Stage)
LAVA Therapeutics N.V.
LVTX
$1.32
$0.021.54%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -23.39% | 60.86% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.31% | -27.46% | |||
| Operating Income | -137.42% | 71.68% | |||
| Income Before Tax | 9.36% | 70.57% | |||
| Income Tax Expenses | -40.79% | 295.83% | |||
| Earnings from Continuing Operations | 12.37% | 67.71% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 12.37% | 67.71% | |||
| EBIT | -137.42% | 71.68% | |||
| EBITDA | -140.62% | 72.16% | |||
| EPS Basic | 12.45% | 67.73% | |||
| Normalized Basic EPS | -2,829.17% | 102.54% | |||
| EPS Diluted | 12.45% | 67.73% | |||
| Normalized Diluted EPS | -2,829.17% | 102.54% | |||
| Average Basic Shares Outstanding | 0.10% | 0.08% | |||
| Average Diluted Shares Outstanding | 0.10% | 0.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||